Yüklüyor......
Engaging the lysosomal compartment to combat B cell malignancies
The combination of rituximab, a type I anti-CD20 mAb, with conventional chemotherapy has significantly improved the outcome of patients with B cell malignancies. Regardless of this success, many patients still relapse with therapy-resistant disease, highlighting the need for the development of mAbs...
Kaydedildi:
| Asıl Yazarlar: | , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Society for Clinical Investigation
2009
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2719949/ https://ncbi.nlm.nih.gov/pubmed/19620776 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI40259 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|